Skip to Content

Pedmark Approval Status

FDA Approved: No
Brand name: Pedmark
Generic name: sodium thiosulfate
Company: Fennec Pharmaceuticals Inc.
Treatment for: Prevention of Cisplatin-Induced Ototoxicity

Pedmark (sodium thiosulfate) is a cisplatin neutralizing agent in development for the protection against hearing loss in pediatric patients receiving cisplatin chemotherapy.

Development Status and FDA Approval Process for Pedmark

DateArticle
Dec 20, 2018Fennec Pharmaceuticals Initiates Rolling New Drug Application to FDA for Pedmark
Mar 22, 2018Fennec Pharmaceuticals Receives Fast Track Designation by FDA for Pedmark

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide